Literature DB >> 17960498

B-cells and humoral immunity in multiple sclerosis. Implications for therapy.

Sangjin Oh1, Cornelia Cudrici, Takahiro Ito, Horea Rus.   

Abstract

B-cells and humoral immunity have been implicated in the pathogenesis of multiple sclerosis. The most common pattern of demyelinating pathology in multiple sclerosis is associated with the deposition of antibodies and the activation of complement, as well as T-cells and macrophages. Plasmapheresis has been found to be an efficient therapeutic approach in patients with this type of pathological lesion. Recent data have indicated that autoantibodies and complement C5b-9 may be involved in lesion formation and might also be beneficial for lesion repair. Thus, the role played by B-cells and humoral immunity is rather complex, and new strategies for targeting B-cell responses are continuing to emerge.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17960498     DOI: 10.1007/s12026-007-8009-6

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  70 in total

1.  Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes.

Authors:  K W Wucherpfennig; I Catz; S Hausmann; J L Strominger; L Steinman; K G Warren
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 2.  C5b-9 complement complex in autoimmune demyelination: dual role in neuroinflammation and neuroprotection.

Authors:  Horea Rus; Cornelia Cudrici; Florin Niculescu
Journal:  Adv Exp Med Biol       Date:  2006       Impact factor: 2.622

Review 3.  B cells and antibodies in CNS demyelinating disease.

Authors:  A H Cross; J L Trotter; J Lyons
Journal:  J Neuroimmunol       Date:  2001-01-01       Impact factor: 3.478

4.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

5.  Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.

Authors:  Olaf Stüve; Sabine Cepok; Birte Elias; Andreas Saleh; Hans-Peter Hartung; Bernhard Hemmer; Bernd C Kieseier
Journal:  Arch Neurol       Date:  2005-10

6.  Plasmapheresis in multiple sclerosis: prospective trial of pheresis and immunosuppression versus immunosuppression alone.

Authors:  R S Tindall; J E Walker; A L Ehle; L Near; J Rollins; D Becker
Journal:  Neurology       Date:  1982-07       Impact factor: 9.910

7.  Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis.

Authors:  Roberta Magliozzi; Sandra Columba-Cabezas; Barbara Serafini; Francesca Aloisi
Journal:  J Neuroimmunol       Date:  2004-03       Impact factor: 3.478

8.  Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects.

Authors:  V Lampasona; D Franciotta; R Furlan; S Zanaboni; R Fazio; E Bonifacio; G Comi; G Martino
Journal:  Neurology       Date:  2004-06-08       Impact factor: 9.910

9.  A double-blind controlled pilot study of plasma exchange versus sham apheresis in chronic progressive multiple sclerosis.

Authors:  P A Gordon; D J Carroll; W S Etches; V Jeffrey; L Marsh; B L Morrice; D Olmstead; K G Warren
Journal:  Can J Neurol Sci       Date:  1985-02       Impact factor: 2.104

10.  Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis.

Authors:  M J Walsh; W W Tourtellotte
Journal:  J Exp Med       Date:  1986-01-01       Impact factor: 14.307

View more
  5 in total

1.  Structural basis for inhibition of complement C5 by the SSL7 protein from Staphylococcus aureus.

Authors:  Nick S Laursen; Natasha Gordon; Stefan Hermans; Natalie Lorenz; Nicola Jackson; Bruce Wines; Edzard Spillner; Jesper B Christensen; Morten Jensen; Folmer Fredslund; Mette Bjerre; Lars Sottrup-Jensen; John D Fraser; Gregers R Andersen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-04       Impact factor: 11.205

2.  Multivalent Soluble Antigen Arrays Exhibit High Avidity Binding and Modulation of B Cell Receptor-Mediated Signaling to Drive Efficacy against Experimental Autoimmune Encephalomyelitis.

Authors:  Brittany L Hartwell; Chad J Pickens; Martin Leon; Cory Berkland
Journal:  Biomacromolecules       Date:  2017-05-17       Impact factor: 6.988

3.  Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis.

Authors:  Oliver Crespo; Stacey C Kang; Richard Daneman; Tamsin M Lindstrom; Peggy P Ho; Raymond A Sobel; Lawrence Steinman; William H Robinson
Journal:  J Clin Immunol       Date:  2011-08-17       Impact factor: 8.317

Review 4.  Complement in multiple sclerosis: its role in disease and potential as a biomarker.

Authors:  G Ingram; S Hakobyan; N P Robertson; B P Morgan
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

Review 5.  Current understanding on the role of standard and immunoproteasomes in inflammatory/immunological pathways of multiple sclerosis.

Authors:  Elena Bellavista; Aurelia Santoro; Daniela Galimberti; Cristoforo Comi; Fabio Luciani; Michele Mishto
Journal:  Autoimmune Dis       Date:  2014-01-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.